secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001724521-25-000066
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus reports 46% confirmed ORR for casdatifan + cabozantinib in ccRCC post-immunotherapy
--------------------------------------------------------------------------------

- Phase 1/1b ARC-20 interim analysis shows 46% cORR (11/24) per RECIST v1.1; median follow-up 5.3 months.
- Response includes 1 complete response (4%) and 10 partial responses (42%); 50% had stable disease.
- Safety evaluable population (n=42) showed acceptable safety profile with no new unexpected risks or overlapping toxicity.
- Study evaluates casdatifan 100mg QD plus cabozantinib 60mg QD in patients with ccRCC who progressed on prior immunotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000066/0001724521-25-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000066/rcus-20250601.htm
  HTML page:      https://secwatch.observer/filing/0001724521-25-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer